CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals (NASDAQ:CNSP) has reported its Q2 2025 financial results and provided updates on its drug development programs. The company maintains a strong cash position of $12.1 million, expected to sustain operations into H2 2026.

The company's lead program, TPI 287, an abeotaxane designed to cross the blood-brain barrier, showed promising results in Phase 1 trials for glioblastoma multiforme (GBM), achieving 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to initiate a Phase 2 study in H1 2026 and engage with FDA on study design in 2025.

For Q2 2025, CNS reported a net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, with R&D expenses of $1.2 million and reduced G&A expenses of $1.2 million.

CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual presentation will be delivered by CEO John Climaco on Tuesday, August 19, 2025, at 2:40 PM ET.

CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO John Climaco presented at the event, sharing insights about his leadership journey and passion for the company's development programs.

The presentation is now available for viewing on virtualinvestorco.com and the Events page in the Investors section of cnspharma.com.

CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The biopharmaceutical company's stock will continue trading on the Nasdaq Capital Market under the same symbol "CNSP" but with a new CUSIP number: 18978H508.

Under this reverse split, every 12 shares will be automatically combined into one share, with proportional adjustments made to outstanding warrants and equity-based awards. The company's authorized shares will be reduced to 25 million, while maintaining a par value of $0.001 per share. Stockholders entitled to fractional shares will receive cash payments instead.

CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced CEO John Climaco's participation in a Virtual Investor CEO Connect segment. During the presentation, Climaco discussed the company's lead program TPI 287 and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.

CNS Pharmaceuticals (NASDAQ:CNSP) has released a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital. The segment focuses on Glioblastoma Multiforme (GBM) treatment landscape and the company's lead product candidate, TPI 287.

Dr. Dunbar, who specializes in brain and spine tumor patient care, discusses the potential of TPI 287 as a treatment for GBM and its possible applications for metastatic tumors. The virtual segment is now available for viewing online.

CNS Pharmaceuticals announced that its Chief Medical Officer, Dr. Sandra Silberman, will present at the 2025 Brain Tumor Biotech Summit in New York. The presentation will focus on TPI 287, the company's drug candidate for glioblastoma treatment. TPI 287 is an abeotaxane that works similarly to other taxanes by stabilizing microtubules and inhibiting cell division. Unlike most taxanes, TPI 287 shows potential to cross the blood-brain barrier. In a Phase 1 trial combining TPI 287 with bevacizumab, the drug showed promising results with 3 Complete Responses and 9 Partial Responses among 23 evaluable patients. The FDA has granted TPI 287 Orphan Drug Designation for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

CNS Pharmaceuticals (NASDAQ:CNSP) reported its Q1 2025 financial results and provided updates on its lead program TPI 287. The company reported a net loss of $4.3 million, up from $3.5 million in Q1 2024, with R&D expenses increasing to $3.2 million. CNS ended Q1 with $13.1 million in cash and subsequently raised an additional $5 million through a public offering in May 2025, extending their cash runway into H2 2026. The company's lead drug candidate, TPI 287, an abeotaxane for treating glioblastoma multiforme (GBM), showed promising Phase 1 results with 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to commence a Phase 2 study around year-end 2025 and will engage with FDA for study design feedback. The company successfully transferred Orphan Drug Designations from Cortice Biosciences for TPI 287 in treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.

CNS Pharmaceuticals (NASDAQ:CNSP) has announced the pricing of a $5 million public offering with a single healthcare-focused institutional investor. The offering includes 3,952,570 shares of common stock priced at $1.265 per share. Additionally, the company will issue Series F Warrants to purchase up to 3,952,570 shares with an exercise price of $1.14 per share, exercisable immediately and expiring in five years.

The offering is expected to close around May 14, 2025. A.G.P./Alliance Global Partners is serving as the sole placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to an effective registration statement on Form S-1.